Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients

Table 3 Mean and peak doses of vasopressors/inotropes used

Doses of vasopressors/ inotropes used
Mean doses μg/kg/minute					Peak doses μg/kg/minute
Epinephrine	Norepinephrine	Dopamine	Dobutamine	Patient	Epinephrine	Norepinephrine	Dopamine	Dobutamine
n	0.07	n	2.86	No.1	n	0.15	n	5.13
n	0.07	n	2.86	No.1	n	(for 2 h)	n	(for 2 h)
n	n	n	2.49	No.2	n	n	n	2.49
n	n	n	2.49	No.2	n	n	n	(for 4.5 h)
n	0.02	n	n	No.3	n	0.02	n	n
n	0.02	n	n	No.3	n	(for 6.3 h)	n	n
n	0.07	n	n	No.4	n	0.08	n	n
n	0.07	n	n	No.4	n	(for 20 h)	n	n
n	0.03	n	3.97	No.5	b	0.04	n	6.66
n	0.03	n	3.97	No.5	b	(for 13 h)	n	(for 34 h)
n	0.05	n	2.38	No.6	n	0.12	n	2.38
n	0.05	n	2.38	No.6	n	(for 24 h)	n	(for 12 h)
n	0.05	n	n	No.7	n	0.1	n	n
n	0.05	n	n	No.7	n	(for 3 h)	n	n
0.13	0.17	n	4.15	No.8	0.22	0.25	n	4.39
0.13	0.17	n	4.15	No.8	(for 11 h)	(for 1.5 h)	n	(for 33 h)
n	0.08	n	n	No.9	n	0.23	n	n
n	0.08	n	n	No.9	n	(for 8 h)	n	n
b	0.06	n	n	No.10	b	0.14	n	n
b	0.06	n	n	No.10	b	(for 0.5 h)	n	n
0.11	n	n	3.79	No.11	0.39	n	n	7.35
0.11	n	n	3.79	No.11	(for 1.5 h)	n	n	(for 11 h)
n	0.06	n	2.28	No.12	n	0.42	n	5.21
n	0.06	n	2.28	No.12	n	(for 2 h)	n	(for 1 h)
n	0.09	n	n	No.13	n	0.2	n	n
n	0.09	n	n	No.13	n	(for 6 h)	n	n
0.03	0.02	3.1	n	No.14	0.06	0.05	3.7	n
0.03	0.02	3.1	n	No.14	(for 3 h)	(for 5 h)	(for 3 h)	n
n	0.03	n	n	No.15	n	0.04	n	n
n	0.03	n	n	No.15	n	(for 46 h)	n	n
0.08	n	1.38	2.96	No.16	0.15	n	1.38	6.4
0.08	n	1.38	2.96	No.16	(for 3 h)	n	(for 1.5 h)	(for 10 h)
4/16	13/16	2/16	8/16		4/16	13/16	2/16	8/16

b, bolus; h, hours; n, none. (in brackets: duration of peak dose application in hours).

ISSN: 1364-8535